A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- Registration Number
- NCT03783442
- Lead Sponsor
- BeiGene
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 649
- Pathologically (histologically) confirmed diagnosis of ESCC
- Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced recurrent or metastatic disease (per American Joint Committee on Cancer 7th Edition), if there is prior neoadjuvant/adjuvant therapy with platinum-based chemotherapy, a treatment-free interval of at least 6 months is required.
Key
- Palliative radiation treatment for ESCC within 4 weeks of study treatment initiation
- Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC
- Received prior therapies targeting programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1) or PD-L2
- Participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta)
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention (clinically significant recurrence requiring an additional intervention within 2 weeks of intervention)
- Evidence of complete esophageal obstruction not amenable to treatment
- Unintentional weight loss ≥ 5% within one month prior to randomization or Nutritional Risk Index (NRI) < 83.5 per investigator's choice
- Locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator.
- Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is ≥ 500 IU/mL or participants with active hepatitis C virus (HCV)
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo + Chemotherapy Placebo Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Tislelizumab + Chemotherapy Fluorouracil (5-FU) Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or * Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Placebo + Chemotherapy Fluorouracil (5-FU) Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Tislelizumab + Chemotherapy Oxaliplatin Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or * Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Tislelizumab + Chemotherapy Cisplatin Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or * Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Tislelizumab + Chemotherapy Capecitabine Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or * Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Tislelizumab + Chemotherapy Paclitaxel Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or * Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Tislelizumab + Chemotherapy Tislelizumab Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or * Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Placebo + Chemotherapy Cisplatin Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Placebo + Chemotherapy Oxaliplatin Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Placebo + Chemotherapy Capecitabine Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines Placebo + Chemotherapy Paclitaxel Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days * Chemotherapy Doublet A: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m\^2 on Days 1 to 5 of each cycle Q3W; * Chemotherapy Doublet B: cisplatin 60-80 mg/m\^2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m\^2 on Days 1 to 14 of each cycle, twice a day; or Chemotherapy Doublet C: cisplatin 60-80 mg/m\^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m\^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m\^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to approximately 3 years and 2 months (as of primary analysis data cut-off date of 28FEB2022) OS is defined as the time from the date of randomization until the date of death due to any cause
- Secondary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Approximately 40 months from date of the first participant randomization PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first
Objective Response Rate (ORR) Approximately 40 months from date of the first participant randomization ORR is defined as the proportion of participants whose best overall response (BOR) is complete response (CR) or partial response (PR) assessed by the investigator per RECIST v1.1
Overall Survival (OS) in the PD-L1 Score ≥ 10% Subgroup Approximately 40 months from date of the first participant randomization OS is defined as the time from the date of randomization until the date of death due to any cause
Duration of Response (DOR) Approximately 40 months from date of the first participant randomization DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever comes first
Health-Related Quality of Life (HRQoL) Assessment of the Participant's Overall Health Status Using European Quality of Life-Core 30 Questionnaire Index (EORTC QLQ-C30) Approximately 40 months from date of the first participant randomization Health-Related Quality of Life (HRQoL) Assessment of the Participant's Overall Health Status Using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Esophageal Cancer Specific Module (EORTC QLQ-OES18) Approximately 40 months from date of the first participant randomization Health-Related Quality of Life (HRQoL) Assessment of the Participant's Overall Health Status Using the Generic Health State Instrument European Quality of Life-5 Dimensions (EuroQol 5D EQ-5D-5L) Approximately 40 months from date of the first participant randomization Number of Participants Experiencing Adverse Events (AEs) Approximately 40 months from date of the first participant randomization
Trial Locations
- Locations (176)
Anhui Provincial Cancer Hospital
🇨🇳Hefei, Anhui, China
Anhui Medical University - The Second Hospital
🇨🇳Hefei, Anhui, China
Xiangyang Central Hospital
🇨🇳Xiangyang, Hubei, China
Hunan Cancer Hospital - GCP Office
🇨🇳Changsha, Hunan, China
The First People's Hospital of Changzhou - Oncology
🇨🇳Changzhou, Jiangsu, China
Nantong Cancer Hospital
🇨🇳Nantong, Jiangsu, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China
The First Affiliated Hospital of Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Shanxi Provincial People's Hospital
🇨🇳Taiyuan, Shanxi, China
Anhui Provincial Hospital - Oncology
🇨🇳Hefei, China
Maidstone and Tunbridge Wells NHS Trust - Kent Oncology Centre
🇬🇧Maidstone, Kent, United Kingdom
Centre Hospitalier Universitaire de Poitiers
🇫🇷Poitiers, Vienne, France
SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii
🇵🇱Olsztyn, Warminsko-mazurskie, Poland
Grand Hôpital de Charleroi - Site Notre-Dame
🇧🇪Charleroi, Hainaut, Belgium
CHU Bordeaux Hôpital Du Haut-Lévêque
🇫🇷Pessac Cedex, Gironde, France
China Medical University Hospital - Oncology - Taichung
🇨🇳Taichung, Taiwan
Chi Mei Medical Center - YongKang - Chi Mei Medical Center
🇨🇳Tainan, Taiwan
Center Oscar Lambret - Alliance Member
🇫🇷Lille, Nord, France
Szpital Wojewodzki w Koszalinie
🇵🇱Koszalin, Pomorskie, Poland
SLK Kliniken Heilbronn GmbH - Klinik für Radiologie, Minimalinvasive Therapien und Nuklearmedizin
🇩🇪Heilbronn, Baden-Württemberg, Germany
Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj Napoca
🇷🇴Cluj-Napoca, Cluj, Romania
Medisprof
🇷🇴Cluj-Napoca, Romania
Royal Marsden NHS Foundation Trust Sutton
🇬🇧London, City Of London, United Kingdom
Beatson West of Scotland Cancer Centre - Oncology
🇬🇧Glasgow, Scotland, United Kingdom
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Coffs Harbour Hospital
🇦🇺Coffs Harbour, Pacific Highway, Australia
Townsville Hospital
🇦🇺Douglas, Queensland, Australia
Antwerp University Hospital
🇧🇪Edegem, Antwerpen, Belgium
UZ Leuven - Campus Gasthuisberg
🇧🇪Leuven, Vlaams Brabant, Belgium
Ballarat Oncology & Haematology Services
🇦🇺Wendouree, Victoria, Australia
UZ Gent - Radiologie
🇧🇪Gent, Oost-Vlaanderen, Belgium
Chinese PLA General Hospital
🇨🇳Beijing, Beijing, China
Zhongshan Hospital Xiamen University
🇨🇳Xiamen, Fujian, China
The First Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College
🇨🇳Shantou, Guangdong, China
Hainan General Hospital - Oncology
🇨🇳Haikou, Hainan, China
Cancer Hospital of Guangxi Medical University
🇨🇳Nanning, Guangxi, China
Affiliated Tumor Hospital of Harbin Medical University
🇨🇳Haerbin, Heilongjiang, China
Henan Cancer Hospital - Oncology
🇨🇳Zhengzhou, Henan, China
Hubei Cancer Hospital - Oncology
🇨🇳Wuhan, Hubei, China
The Affiliated Hospital of Xuzhou Medical University - Radiology
🇨🇳Xuzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
CHRU de Besançon- Hôpital Jean Minjoz
🇫🇷Besançon Cedex, Doubs, France
Institut Hospitalier Franco-Britannique (IHFB) - Levallois-Perret - 4 Rue Kleber
🇫🇷Levallois-Perret, Hauts-de-Seine, France
University Hospital Hamburg- Eppendorf
🇩🇪Hamburg, Germany
Kyushu Medical Center - Gastroenterological Surgery
🇯🇵Fukuoka, Hukuoka, Japan
Centrul de Oncologie Sf. Nectarie
🇷🇴Craiova, Dolj, Romania
Institutul Clinic Fundeni
🇷🇴Bucuresti, Romania
Orenburg Regional Clinical Oncology Center
🇷🇺Orenburg, Orenburgskaya Oblast, Russian Federation
The First Saint-Petersburg State Medical University named after Academician I.P. Pavlov
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
Hospital Universitario Central de Asturias
🇪🇸Oviedo, Asturias, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Kaohsiung Veterans General Hospital - Thoracic Surgery
🇨🇳Kaohsiung, Taiwan
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital
🇬🇧London, City Of London, United Kingdom
Smilow Cancer Hospital at Yale-New Haven - Neurology
🇺🇸New Haven, Connecticut, United States
Allegheny General Hospital (AGH)
🇺🇸Pittsburgh, Pennsylvania, United States
Medical University of South Carolina Hollings Cancer Center
🇺🇸Charleston, South Carolina, United States
University of Texas Health Science Center of San Antonio
🇺🇸San Antonio, Texas, United States
Renovatio Clinical
🇺🇸The Woodlands, Texas, United States
Ashford Cancer Centre Research
🇦🇺Kurralta Park, South Australia, Australia
St Vincent's Hospital
🇦🇺Fitzroy, Victoria, Australia
Royal Hobart Hospital
🇦🇺Hobart, Tasmania, Australia
Institut Jules Bordet - Oncologie Médicale
🇧🇪Anderlecht, Brussels Capital Region, Belgium
AZ Sint-Jan Brugge - Oostende AV - Campus Sint-Jan - Oncology
🇧🇪Brugge, West-Vlaanderen, Belgium
CHC Mont Legia
🇧🇪Liège, Belgium
CHU Liège Sart Tilman
🇧🇪Liège, Belgium
The Second Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
Beijing Friendship Hospital - Oncology
🇨🇳Beijing, Beijing, China
The Fifth Medical Center of Chinese PLA General Hospital
🇨🇳Beijing, Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China
Fujian Provincial Cancer Hospital - Oncology
🇨🇳Fuzhou, Fujian, China
Peking Union Medical College Hospital - Oncology
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of Fujian Medical University
🇨🇳Fuzhou, Fujian, China
The Sixth Affiliated Hospital of Sun Yat-Sen University
🇨🇳Guangzhou, Guangdong, China
Guangdong Province Traditional Chinese Medical Hospital
🇨🇳Guangzhou, Guangdong, China
The First Affiliated Hospital of Zhengzhou University - Oncology
🇨🇳Henan, Henan, China
The First Affiliated Hospital of Xinxiang Medical University
🇨🇳Xinxiang, Henan, China
Jiangsu Province Hospital
🇨🇳Nanjing, Jiangsu, China
Affiliated Hospital of Jiangnan University
🇨🇳Wuxi, Jiangsu, China
Liaoning Cancer Hospital & Institute - Medical Oncology - Oncology
🇨🇳Shenyang, Liaoning, China
Northern Jiangsu People's Hospital
🇨🇳Yangzhou, Jiangsu, China
Linyi Cancer Hospital
🇨🇳Linyi, Shandong, China
Shandong Cancer Hospital and Institute, Shandong First Medical University
🇨🇳Jinan, Shandong, China
Quanzhou First Hospital - Radiotherapy/Nuclear Medicine
🇨🇳Quanzhou, Quanzhou, China
WeiFang People's Hospital
🇨🇳Weifang, Shandong, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, Tianjin, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Fakultní Nemocnice Olomouc
🇨🇿Olomouc, Czechia
The First Affiliated Hospital of Xiamen University - Oncology
🇨🇳Xiamen, China
Nemocnice Na Bulovce
🇨🇿Praha 8, Czechia
Hôpital Morvan - CHRU de Brest - cancérologie et d'hématologie
🇫🇷Brest Cedex, Bretagne, France
Thomayerova nemocnice
🇨🇿Praha 4, Czechia
ICO
🇫🇷Saint-Herblain, Loire-Atlantique, France
Hopital Saint-Antoine / Service d'Hepato-Gastro-Enterologie
🇫🇷Paris Cedex 12, Paris, France
Centre Léon Bérard
🇫🇷Lyon, Rhône, France
Hopital Europeen Georges Pompidou - Digestive Oncology
🇫🇷Paris, France
University Hospital Tuebingen
🇩🇪Tuebingen, Baden-Württemberg, Germany
Groupe Hospitalier Paris Saint Joseph - Oncologie
🇫🇷Paris, France
Johannes Wesling Klinikum Minden
🇩🇪Minden, Nordrhein-Westfalen, Germany
Universitätsmedizin Mainz
🇩🇪Mainz, Rheinland-Pfalz, Germany
University Hospital Of Leipzig
🇩🇪Leipzig, Sachsen, Germany
Ospedale Umberto I, AOU Ospedali Riuniti Umberto I - GM.Lanc - Oncologia Medica
🇮🇹Ancona, Italy
Istituto Oncologico Veneto IOV-IRCCS
🇮🇹Padova, Italy
Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori', IRCCS - Laboratorio
🇮🇹Meldola, Emilia-Romagna, Italy
Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori
🇮🇹Napoli, Italy
SO S.Chiara, AOU Pisana - Oncologia 2
🇮🇹Pisa, Italy
Ieo, Irccs
🇮🇹Milano, Italy
National Cancer Center Hospital East - Gastrointestinal Oncology
🇯🇵Kashiwa, Chiba, Japan
Asst Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Kobe City Medical Center General Hospital - Medical Oncology
🇯🇵Kobe, Hyogo, Japan
National Hospital Organization Kyushu Cancer Center - GI and Medical Oncology
🇯🇵Fukuoka, Hukuoka, Japan
Kanagawa Cancer Center - Gastroenterological surgery
🇯🇵Yokohama, Kanagawa, Japan
Kagawa University Hospital - Oncology
🇯🇵Kita-gun, Kagawa, Japan
Kindai University Nara Hospital
🇯🇵Ikoma, Osaka, Japan
University Hospital, Kyoto Prefectural Univ of Medicine - Gastroenterology
🇯🇵Kamigyō-ku, Kyoto, Japan
Osaka University Hospital - Medical Oncology
🇯🇵Suita, Osaka, Japan
National Cancer Center Hospital - Gastrointestinal Oncology
🇯🇵Chuo Ku, Tokyo, Japan
Akita University Hospital - Pediatrics
🇯🇵Akita-shi, Japan
Kansai Rosai Hospital - Gastroenterological Surgery
🇯🇵Amagasaki, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Hyogo Cancer Center
🇯🇵Akashi, Japan
Hiroshima University Hospital - Gastrointestinal Surgery
🇯🇵Hiroshima, Japan
Kyoto University Hospital
🇯🇵Kyoto, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Osaka International Cancer Institute - Clinical Oncology
🇯🇵Osaka, Japan
Saitama Cancer Center - Gastroenterology
🇯🇵Saitama, Japan
Seoul National University Bundang Hospital - Hematology/Oncology
🇰🇷Seongnam-si, Gyeonggido [Kyonggi-do], Korea, Republic of
CHA Bundang Medical Center, CHA University - Oncology
🇰🇷Seongnam-si, Gyeonggido, Korea, Republic of
Chonnam National University Hwasun Hospital - Hematology and Oncology Clinic
🇰🇷Hwasun, Jeonranamdo [Chollanam-do], Korea, Republic of
Gachon University Gil Medical Center - Oncology
🇰🇷Incheon, Incheon Gwang'yeogsi [Inch'n-K, Korea, Republic of
SMG-SNU Boramae Medical Center - Oncology
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of
Samsung Medical Center - Hematology-Oncology
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of
Korea University Guro Hospital - Hematology-Oncology
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of
Asan Medical Center - Oncology
🇰🇷Seoul, Korea, Republic of
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
🇵🇱Warszawa, Mazowieckie, Poland
Szpital Specjalist. w Brzozowie,Podkarpacki Ośrodek Onkologi
🇵🇱Brzozow, Podkarpackie, Poland
Clinical Research Center Sp. z o.o., Medic-R Sp. K.
🇵🇱Poznan, Wielkopolskie, Poland
Radiotherapy Center Cluj
🇷🇴Floreşti, Cluj, Romania
Centrul de Oncologie Euroclinic
🇷🇴Iaşi, Romania
Arkhangelsk Regional Clinical Oncological Dispensary
🇷🇺Arkhangelsk, Arkhangel'skaya Oblast', Russian Federation
Spitalul Clinic Coltea
🇷🇴Bucuresti, Romania
Leningrad Regional Oncology Dispensary
🇷🇺Kuz'molovskiy, Leningradskaya Oblast, Russian Federation
Rostov Research Institute of Oncology (RRIO)
🇷🇺Rostov-Na-Donu, Rostovskaya Oblast, Russian Federation
City Oncology Dispensary
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
Ivanovo Regional Oncology Dispensary
🇷🇺Ivanovo, Russian Federation
Petrov Research Institute of Oncology
🇷🇺Saint Petersburg, Russian Federation
Institut Catalá d´Oncología (I.C.O.)
🇪🇸L'Hospitalet De Llobregat, Barcelona, Spain
Hospital Madrid Norte Sanchinarro
🇪🇸Sanchinarro, Madrid, Spain
Hospital Universitario Vall d'Hebrón
🇪🇸Barcelona, Spain
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
H.U.V.Arrixaca
🇪🇸Murcia, Spain
Hospital Universitario Virgen De La Victoria
🇪🇸Málaga, Spain
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology
🇨🇳Kaohsiung, Taiwan
Chi Mei Hospital, Liouying - Department of Oncology
🇨🇳Tainan, Taiwan
Guys and St Thomas' Hospital
🇬🇧London, City Of London, United Kingdom
Mount Vernon Cancer Centre
🇬🇧Northwood, England, United Kingdom
The Christie NHS Foundation Trust - Oak Road Treatment Centr
🇬🇧Manchester, United Kingdom
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of
Keimyung University Dongsan Medical Center
🇰🇷Daegu, Korea, Republic of
Smilow Cancer Hospital At Yale
🇺🇸New Haven, Connecticut, United States
Coffs Harbour Base Hospital
🇦🇺Coffs Harbour, New South Wales, Australia
St Vincents Hospital Melbourne
🇦🇺Fitzroy, Victoria, Australia
Institut Jules Bordet
🇧🇪Anderlecht, Belgium
Az Sint Jan Brugge
🇧🇪Brugge, Belgium
Grand Hopital de Charleroi Site Notre Dame
🇧🇪Charleroi, Belgium
UZ GENT
🇧🇪Gent, Belgium
University Hospitals Leuven
🇧🇪Leuven, Belgium
Chc Montlegia
🇧🇪Liege, Belgium
Anhui Provincial Hospital
🇨🇳Hefei, Anhui, China
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
🇨🇳Hefei, Anhui, China
The Second Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
Beijing Friendship Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
The Fifth Medical Center of Chinese Pla General Hospital
🇨🇳Beijing, Beijing, China
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China